임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 21-06-10 11:28
논문번호 272
논문제목(영문) One-year Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffolds in the Setting of Acute Myocardial Infarction.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Kim Y, Bae S,
교신저자명 Jeong MH
공동저자명 Ahn Y, Kim CJ, Cho MC, Baumbach A, Gogas BD, King SB 3rd
게제년월일 2020-07-09
ISSN 1932-6203
Impact Factor 2.74
학술지명 PLOS ONE
서지사항 0집 / 15권 / 7호,   페이지(e0235673 - e0235673)
요약초록문
(Abstract) 입력		 Background and objectives This study sought to compare clinical outcomes between bioresorbable scaffolds (BRS) and durable polymer everolimus-eluting metallic stents (DP-EES) in patients with acute myocardial infarction (AMI) undergoing successful percutaneous coronary intervention (PCI). Methods From March 2016 to October 2017, 952 patients with AMI without cardiogenic shock undergoing successful PCI with BRS (n = 136) or DP-EES (n = 816) were enrolled from a multicenter, observational Korea Acute Myocardial Infarction Registry. Results In the crude population, there was no significant difference in the 1-year rate of device-oriented composite endpoint (DOCE) and device thrombosis between the BRS and DP-EES groups (2.2% vs. 4.8%, hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.13-1.41, p = 0.163; 0.7% vs. 0.5%, HR 1.49, 95% CI 0.16-13.4, p = 0.719, respectively). BRS implantation was opted in younger patients (53.7 vs. 62.6 years, p < 0.001) with low-risk profiles, and intravascular image-guided PCI was more preferred in the BRS group (60.3% vs. 27.2%, p < 0.001). Conclusions At 1-year follow-up, no differences in the rate of DOCE and device thrombosis were observed between patients with AMI treated with BRS and those treated with DP-EES. Our data suggest that imaging-guided BRS implantation in young patients with low risk profiles could be a reasonable strategy in the setting of AMI.
파일  C272. One-year Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffo~.pdf (2.2M) DATE : 2021-06-10 11:28:12